Samsung Prepping For First Biosimilar Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Samsung Bioepis' biosimilar version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) is set to become the firm’s first biosimilar product to hit the market, possibly being released in South Korea late this year and in Europe in the first half of next year.